Drugs / AGS-8M4
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01016054 | Oct 2009 → Apr 2010 | carcinoma, ovarian cancer | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 1 | NCT00816764 | Oct 2008 → Jun 2010 | carcinoma, ovarian cancer | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGS-8M4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00816764 ↗ |
| Route | Intravenous | “AGS-8M4 will be administered as an IV infusion” NCT00816764 ↗ |